Ligand Pharmaceuticals (LGND) Stock Shrugs Off Q3 Earnings Loss

Ligand Pharmaceuticals just released its Q3 2026 report and the stock barely moved. Shares slipped about 0.5%, a modest reaction for a biotech licensor that reported a basic earnings per share loss of US$1.43 on revenue of US$78.7 million.

That muted move suggests that sentiment may be lagging the central issue of profitability pressure. A company that recently reported a trailing net profit margin of 20.3% is now asking investors to look past a new net income loss and focus instead on the longer earnings profile.

Love Ligand Pharmaceuticals’ high trailing net margin but concerned about the fresh earnings loss this quarter? Filter for biotechs with solid profits and cleaner income statements using our list of solid balance sheet and fundamentals stocks (23 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$78.7 million vs. US$115.5 million (lower period-on-period top line)
• Net Income/Loss (Q3 2026 vs Q3 2025): net loss of US$28.5 million vs. net income of US$117.3 million (swing from profit to loss)
• Basic EPS (Q3 2026 vs Q3 2025): loss of US$1.43 per share vs. earnings of US$5.99 per share (moved from positive to negative EPS)
• Trailing Net Profit Margin (Last 12 Months vs Prior Year): 20.3% vs. 19.3% (slight improvement in overall profitability ratio)

Earnings can swing around from quarter to quarter, while cash flows tend to show what investors are really paying for. When you look at Ligand Pharmaceuticals' cash generation in isolation, the stock could be a notable 26% undervalued.

Evaluating Ligand’s Royalty Scale Milestones

The bullish story around Ligand Pharmaceuticals hinges on turning a lean cost base and a bigger royalty pool into earnings power.

"The pivot to a pure royalty aggregation model, combined with the reduction in operating expenses from about US$90 million to about US$40 million and a lean team of roughly 40 employees plus an 18 person deal organization, points to substantial operating leverage that can flow through to net margins and earnings."

Q3 tells a mixed version of that promise. Royalty revenue rose 51% year on year, helped by the XOMA assets and new deals like Ryjunea and AvenCell. Yet the quarter still delivered a net loss of US$28.5 million and a basic EPS loss of US$1.43, so the operating leverage argument rests more on the reaffirmed 2026 profit guidance than on this single period.

One Narrative disagrees with today's price. → See where this Narrative says Ligand Pharmaceuticals should trade.

Ligand Bear Case: Royalty Concentration Risk Under The Microscope

Bears argue that Ligand Pharmaceuticals has hitched too much of its earnings future to a handful of royalty engines.

"The shift to a pure royalty aggregation model with a much smaller internal cost base concentrates results in a relatively small set of high-contribution royalty streams. Any slower uptake, payer pressure or competitive entries in key programs such as Filspari, Ohtuvayre or Qarziba could weigh disproportionately on royalty revenue growth and adjusted EPS."

Q3 royalty revenue rose 51% and 2026 adjusted EPS guidance moved higher, which both cut against fears of an immediate squeeze. The problem is the income statement. A US$28.5 million net loss and basic EPS loss of US$1.43 show that concentration risk has not yet been offset by cost discipline or portfolio breadth. The raised guidance leans on partners delivering, while this quarter’s GAAP loss underlines that the model still has something to prove.

Hunt For Mispriced Earnings Stories

Ligand Pharmaceuticals just reported a complex quarter where the share price barely moved. The real opportunity is hunting for stocks that could be undervalued before the market reassesses them.

• Company 1 - 40% below our estimate - expand tracker and control hardware into storage, inverter and non tracker solutions for utility-scale projects.
• Company 2 - 24% below our estimate - convert rising demand for grid modernization and aerospace programs into higher value diagnostic and RF testing contracts.
• Company 3 - 49% below our estimate - run a high return financial super app domestically while testing whether its marketplace model can succeed abroad.

Three companies from the same screener. Open the full list of 30 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com